Opendata, web and dolomites

JOINTPROMISE SIGNED

PRECISION MANUFACTURING OF MICROENGINEERED COMPLEX JOINT IMPLANTS

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 JOINTPROMISE project word cloud

Explore the words cloud of the JOINTPROMISE project. It provides you a very rough idea of what is the project "JOINTPROMISE" about.

breakthroughs    defects    regenerating    living    bioprinting    grade    prevalent    disease    clinical    shift    rate    automated    containing    paves    adopting    bone    building    precise    predictively    structures    defect    implantation    blocks    there    possess    oa    osteoarthritis    producing    integration    patterned    feasibility    engineered    cartilaginous    unmet    entire    mostly    strive    jointpromise    platform    underlying    efficacy    volume    affordable    surface    ageing    inbuilt    demand    3d    biological    rising    microtissue    robotics    animal    hence    humans    repair    scaled    implants    microtissues    joint    tissue    socioeconomic    solution    bioreactor    regeneration    convincing    time    osteochondral    regenerative    prevent    models    model    population    25    minipig    patient    joints    society    paradigm    biologic    allowed    execute    implant    cartilage    structure    cover    manufacturing    articular    adult    vascularised    organoid    technologies    deep    gmp    manual    arthritic   

Project "JOINTPROMISE" data sheet

The following table provides information about the project.

Coordinator
KATHOLIEKE UNIVERSITEIT LEUVEN 

Organization address
address: OUDE MARKT 13
city: LEUVEN
postcode: 3000
website: www.kuleuven.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 7˙901˙115 €
 EC max contribution 7˙901˙115 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2019-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) coordinator 1˙683˙000.00
2    FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. DE (MUNCHEN) participant 1˙745˙487.00
3    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) participant 1˙694˙275.00
4    POIETIS FR (PESSAC) participant 1˙436˙687.00
5    IDRYMA TECHNOLOGIAS KAI EREVNAS EL (IRAKLEIO) participant 783˙750.00
6    STEMCELL TECHNOLOGIES UK LTD UK (CAMBRIDGE) participant 557˙915.00

Map

 Project objective

There is convincing evidence, in animal models and in humans, that deep osteochondral defects of the joint surface lead to a high rate of osteoarthritis (OA) over time. The disease process in OA, the most prevalent arthritic disease affecting 25% of the adult population, involves the entire joint affecting both the articular cartilage and the underlying bone. Hence it is crucial to consider the entire osteochondral unit as a target for repair. Tissue engineered implants could provide a solution for the regeneration of this type of defects and prevent the development of OA. This project aims to address this unmet clinical need by developing complex joint implants that will possess the spatially inbuilt biologic information for regenerating these challenging defects. Breakthroughs in organoid technologies have allowed the development of cartilaginous microtissue structures that can predictively execute regenerative programmes upon implantation. These microtissues can be used as building blocks for bottom-up 3D bioprinting of living joint implants. In order to be able to produce scaled-up implants containing at the same time a highly precise structure, integration of bioprinting technologies is needed. Moreover in order to cover rising clinical demand the whole manufacturing process, which is mostly manual today, will need to be automated adopting robotics, bioprinting and bioreactor technologies. In order to demonstrate implant feasibility and efficacy, large osteochondral defect repair will be studied in the minipig, a large animal model relevant to the patient. Taken together we strive to develop an automated, GMP-grade platform producing large, patterned and vascularised joint implants providing also a paradigm shift for generic automated manufacturing of organoid-based tissue implants. JOINTPROMISE paves the way for high-volume, affordable production of entire biological joints, addressing a major socioeconomic challenge of the European ageing society.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "JOINTPROMISE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "JOINTPROMISE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

Vacc-iNTS (2019)

Advancing a GMMA-based vaccine against invasive non-typhoidal salmonellosis through Phase 1 trial in Europe and sub-Saharan Africa

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

FURTHER (2019)

Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients with Bone Metastasis

Read More